The safety of incretin based drugs.
作者信息
Montori Victor M
机构信息
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA.
出版信息
BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779.
PMID:24764568
Abstract
摘要
相似文献
1
The safety of incretin based drugs.
BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779.
2
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167.
3
ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
Ann Intern Med. 2015 Jun 16;162(12):JC12. doi: 10.7326/ACPJC-2015-162-12-012.
4
Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Diabetes Care. 2015 Jul;38(7):e106-7. doi: 10.2337/dc15-0367.
5
Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Diabetes Care. 2015 Jul;38(7):e108-9. doi: 10.2337/dc15-0675.
6
Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Diabetes Res Clin Pract. 2015 Dec;110(3):e13-7. doi: 10.1016/j.diabres.2015.10.014. Epub 2015 Oct 23.
7
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z.
8
Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
BMJ. 2014 Apr 24;348:g2780. doi: 10.1136/bmj.g2780.
9
Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Diabetes Care. 2015 Jun;38(6):1089-98. doi: 10.2337/dc13-2983. Epub 2015 Jan 29.
10
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
BMJ. 2013 Jul 10;347:f4386. doi: 10.1136/bmj.f4386.
引用本文的文献
1
Drug therapies in type 2 diabetes: an era of personalised medicine.
Clin Med (Lond). 2016 Oct;16(5):441-447. doi: 10.7861/clinmedicine.16-5-441.
2
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
Diabetes Metab Syndr Obes. 2015 Aug 10;8:363-86. doi: 10.2147/DMSO.S34418. eCollection 2015.
Zotero 插件